BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37024829)

  • 1. Whole-exome mutational landscape and molecular marker study in mucinous and clear cell ovarian cancer cell lines 3AO and ES2.
    Li J; Liang H; Xiao W; Wei P; Chen H; Chen Z; Yang R; Jiang H; Zhang Y
    BMC Cancer; 2023 Apr; 23(1):321. PubMed ID: 37024829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromosome instability region analysis and identification of the driver genes of the epithelial ovarian cancer cell lines A2780 and SKOV3.
    Li J; Chen Z; Xiao W; Liang H; Liu Y; Hao W; Zhang Y; Wei F
    J Cell Mol Med; 2023 Nov; 27(21):3259-3270. PubMed ID: 37525498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks.
    Murakami R; Matsumura N; Brown JB; Higasa K; Tsutsumi T; Kamada M; Abou-Taleb H; Hosoe Y; Kitamura S; Yamaguchi K; Abiko K; Hamanishi J; Baba T; Koshiyama M; Okuno Y; Yamada R; Matsuda F; Konishi I; Mandai M
    Am J Pathol; 2017 Oct; 187(10):2246-2258. PubMed ID: 28888422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
    JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational heterogeneity in non-serous ovarian cancers.
    Teer JK; Yoder S; Gjyshi A; Nicosia SV; Zhang C; Monteiro ANA
    Sci Rep; 2017 Aug; 7(1):9728. PubMed ID: 28852190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implications of next-generation sequencing-based panel tests for malignant ovarian tumors.
    Saotome K; Chiyoda T; Aimono E; Nakamura K; Tanishima S; Nohara S; Okada C; Hayashi H; Kuroda Y; Nomura H; Susumu N; Iwata T; Yamagami W; Kataoka F; Nishihara H; Aoki D
    Cancer Med; 2020 Oct; 9(20):7407-7417. PubMed ID: 32813918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exome-wide Sequencing Shows Low Mutation Rates and Identifies Novel Mutated Genes in Seminomas.
    Cutcutache I; Suzuki Y; Tan IB; Ramgopal S; Zhang S; Ramnarayanan K; Gan A; Lee HH; Tay ST; Ooi A; Ong CK; Bolthouse JT; Lane BR; Anema JG; Kahnoski RJ; Tan P; Teh BT; Rozen SG
    Eur Urol; 2015 Jul; 68(1):77-83. PubMed ID: 25597018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pharmacological concentrations of estrogens on growth of 3AO human ovarian cancer cells.
    Li ZB; Chen YX; Zhao JY; Lu J
    Yi Chuan Xue Bao; 2006 Sep; 33(9):782-92. PubMed ID: 16980124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and clinical significance of hypoxia-inducible factor 1α, Snail and E-cadherin in human ovarian cancer cell lines.
    Zhang Y; Fan N; Yang J
    Mol Med Rep; 2015 Sep; 12(3):3393-3399. PubMed ID: 25975373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of PI3K/Akt/NF-κB signal pathway on FSH facilitation on cell proliferation and invasion by human epithelial ovarian cancer].
    Xu CL; Lu XL; Yan XN; Wang HL; Chen SQ
    Zhonghua Fu Chan Ke Za Zhi; 2012 Feb; 47(2):134-8. PubMed ID: 22455747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing.
    Lee JY; Yoon JK; Kim B; Kim S; Kim MA; Lim H; Bang D; Song YS
    BMC Cancer; 2015 Feb; 15():85. PubMed ID: 25881093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expressions and significance of cyclinD1 in epithelial ovarian cancer cell 3AO].
    Dai J; Zhang PH; Liu PS; Qu HH
    Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(5):351-3. PubMed ID: 22490843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.
    Hunter SM; Anglesio MS; Ryland GL; Sharma R; Chiew YE; Rowley SM; Doyle MA; Li J; Gilks CB; Moss P; Allan PE; Stephens AN; Huntsman DG; deFazio A; Bowtell DD; ; Gorringe KL; Campbell IG
    Oncotarget; 2015 Nov; 6(35):37663-77. PubMed ID: 26506417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
    Kim SI; Lee JW; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
    Gynecol Oncol; 2018 Feb; 148(2):375-382. PubMed ID: 29233531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
    Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
    Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Mutational Status, Spheroid Formation, and Drug Response of a New Genomically-Stable Human Ovarian Clear Cell Carcinoma Cell Line, 105C.
    Kolendowski B; Valdes YR; Hirte H; Itamochi H; Lee W; Carey M; Shepherd TG; DiMattia GE
    Cells; 2020 Nov; 9(11):. PubMed ID: 33153119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low programmed cell death 5 expression is a prognostic factor in ovarian cancer.
    Gao L; Ye X; Ma RQ; Cheng HY; Han HJ; Cui H; Wei LH; Chang XH
    Chin Med J (Engl); 2015 Apr; 128(8):1084-90. PubMed ID: 25881604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification three LncRNA prognostic signature of ovarian cancer based on genome-wide copy number variation.
    Zheng M; Hu Y; Gou R; Nie X; Li X; Liu J; Lin B
    Biomed Pharmacother; 2020 Apr; 124():109810. PubMed ID: 32000042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histotype-specific copy-number alterations in ovarian cancer.
    Huang RY; Chen GB; Matsumura N; Lai HC; Mori S; Li J; Wong MK; Konishi I; Thiery JP; Goh L
    BMC Med Genomics; 2012 Oct; 5():47. PubMed ID: 23078675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
    BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.